Abstract
Introduction Polycythemia vera (PV) is the most frequent among the Philadelphia-negative myeloproliferative neoplasms (MPNs).1 PV is characterized by excessive myeloid cells production secondary to mutations in the Janus kinase 2 (JAK2) gene.2,3 The incidence rate is higher in the sixth decade of life and among males.4 Clinical phenotype is dominated by systemic symptoms, pruritus, and microvascular disturbances; splenomegaly may be detected in 30% of cases.5 In the long term, what impacts outcomes is the increased risk of thrombosis and evolution into post-PV myelofibrosis (PPV-MF) or blast phase (BP).6
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
